Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
The company is bringing precision therapies for gynaecological cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Subscribe To Our Newsletter & Stay Updated
